Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo

Radiotherapy and Oncology

Volumn 102, Issue 3, 2012, Pages 444-449

  Gurtner, Kristin ^a,b   Hessel, Franziska ^a,b   Eicheler, Wolfgang ^a,b   Dörfler, Annegret ^a,b   Zips, Daniel ^a,b   Heider, Karl Heinz ^c   Krause, Mechthild ^a,b   Baumann, Michael ^a,b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Helmholtz Zentrum Dresden Rossendorf   (Germany)

^c BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

Author keywords

Antibody; Bivatuzumab mertansine; CD44v6; Combined treatment; Fractionated irradiation; Local tumour control; Molecular targeting

Indexed keywords

BIVATUZUMAB MERTANSINE; CD44V6 ANTIGEN; PHOSPHATE BUFFERED SALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; HYPOPHARYNX CARCINOMA; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; HYPOPHARYNGEAL NEOPLASMS; MALE; MAYTANSINE; MICE; TUMOR BURDEN;

EID: 84857910221     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2011.10.013     Document Type: Article

References (46)

1. K.H. Heider, H. Kuthan, G. Stehle, and G. Munzert CD44v6: a target for antibody-based cancer therapy Cancer Immunol Immunother 53 2004 567 579 (Pubitemid 38858330)
2. U. Günthert, M. Hofmann, and W. Rudy A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells Cell 65 1991 13 24 (Pubitemid 121001209)
3. G.R. Screaton, M.V. Bell, J.I. Bell, and D.G. Jackson The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat J Biol Chem 268 1993 12235 12238 (Pubitemid 23182367)
4. G.R. Screaton, M.V. Bell, D.G. Jackson, F.B. Cornelis, U. Gerth, and J.I. Bell Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons Proc Natl Acad Sci U S A 89 1992 12160 12164 (Pubitemid 23004805)
5. S. Remillard, L.I. Rebhun, G.A. Howie, and S.M. Kupchan Antimitotic activity of the potent tumor inhibitor maytansine Science 189 1975 1002 1005
6. B.F. Issell, and S.T. Crooke Maytansine Cancer Treat Rev 5 1978 199 207 (Pubitemid 9109517)
7. R.V. Chari Immunoconjugates containing novel maytansinoids: promising anticancer drugs Cancer Res 52 1992 127 131
8. B.M. Tijink, J. Buter, R. de Bree, and A. Phase A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus Clin Cancer Res 12 2006 6064
9. A. Sauter, C. Kloft, and S. Gronau Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck Int J Oncol 30 2007 927 935
10. U. Rupp, E. Schoendorf-Holland, and M. Eichbaum Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study CLINICAL REPORTS. Anti-Cancer Drugs 18 2007 477 485 (Pubitemid 46712412)
11. M. Baumann, C. Liertz, H. Baisch, T. Wiegel, J. Lorenzen, and H. Arps Impact of overall treatment time of fractionated irradiation on local control of human FaDu squamous cell carcinoma in nude mice Radiother Oncol 32 1994 137 143 (Pubitemid 24270735)
12. C. Petersen, D. Zips, and M. Krause Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation Int J Radiat Oncol Biol Phys 51 2001 483 493 (Pubitemid 32884296)
13. M. Krause, G. Ostermann, and C. Petersen Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation Radiother Oncol 76 2005 162 167 (Pubitemid 41725443)
14. A. Yaromina, D. Zips, and H.D. Thames Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice. The need for a multivariate approach in biomarker studies Radiother Oncol 81 2006 122 129 (Pubitemid 44780780)
15. C. Petersen, D. Zips, M. Krause, W. Volkel, H.D. Thames, and M. Baumann Recovery from sublethal damage during fractionated irradiation of human FaDu SCC Radiother Oncol 74 2005 331 336 (Pubitemid 40349144)
16. M. Krause, F. Hessel, D. Zips, F. Hilberg, and M. Baumann Adjuvant inhibition of the epidermal growth factor receptor after fractionated irradiation of FaDu human squamous cell carcinoma Radiother Oncol 72 2004 95 101 (Pubitemid 38952866)
17. M. Krause, J. Prager, and X. Zhou EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: Differential response of cancer stem cells and nontumourigenic cells? Radiother Oncol 83 2007 316 325 (Pubitemid 46915543)
18. M. Baumann, W. DuBois, and H.D. Suit Response of human squamous cell carcinoma xenografts of different sizes to irradiation: relationship of clonogenic cells, cellular radiation sensitivity in vivo, and tumor rescuing units Radiat Res 123 1990 325 330 (Pubitemid 20327905)
19. A. Yaromina, M. Krause, and H. Thames Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation Radiother Oncol 83 2007 304 310 (Pubitemid 46915546)
20. M. Baumann, W. Dubois, A. Pu, J. Freeman, and H.D. Suit Response of xenografts of human malignant gliomas and squamous cell carcinomas to fractionated irradiation Int J Radiat Oncol Biol Phys 23 1992 803 809
21. F. Hessel, M. Krause, and A. Helm Differentiation status of human squamous cell carcinoma xenografts does not appear to correlate with the repopulation capacity of clonogenic tumour cells during fractionated irradiation Int J Radiat Biol 80 2004 719 727 (Pubitemid 40126088)
22. A.L. Zietman, H.D. Suit, J.R. Ramsay, V. Silobrcic, and R.S. Sedlacek Quantitative studies on the transplantability of murine and human tumors into the brain and subcutaneous tissues of NCr/Sed nude mice Cancer Res 48 1988 6510
23. M. Krause, C. Schütze, and C. Petersen Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC Radiother Oncol 74 2005 109 115 (Pubitemid 40331867)
24. A. Yaromina, H. Thames, and X. Zhou Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation Radiother Oncol 96 2010 116 122
25. P.K.E. Borjesson, E.J. Postema, and J.C. Roos Phase I Therapy Study with 186Re-labeled Humanized Monoclonal Antibody BIWA 4 (Bivatuzumab) in Patients with Head and Neck Squamous Cell Carcinoma Clin Cancer Res 9 2003 3961
26. D.R. Colnot, J.C. Roos, and R. de Bree Safety, biodistribution, pharmacokinetics, and immunogenicity of 99m Tc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck Cancer Immunol Immunother 52 2003 576 582 (Pubitemid 37056133)
27. E.J. Postema, P.K. Borjesson, and W.C. Buijs Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer J Nucl Med 44 2003 1690 1699 (Pubitemid 39663345)
28. Hoinkis C, Lehmann D, Geyer P. Dose distribution within a tumor located on a mouse leg: Measurement, Monte Carlo Calculation and Literature. Radioth Oncol 2001;61, Supplement 1:95.
29. A.M. Walker, and H.D. Suit Assessment of local tumor control using censored tumor response data Int J Radiat Oncol Biol Phys 9 1983 383 386 (Pubitemid 13055184)
30. M.C. De Jong, J. Pramana, and J.E. van der Wal CD44 expression predicts local recurrence after radiotherapy in larynx cancer Clin Can Res 16 2010 5329
31. M. Baumann, and M. Krause CD44: A Cancer Stem Cell-Related Biomarker with Predictive Potential for Radiotherapy Clin Cancer Res 16 2010 5091
32. Heider, K. H., Kalat, M., Patzelt, A., Baum, A., Küpcü, Z., Adolf,G.R. Single-Agent Efficacy of Bivatuzumab Mertansine, an Immunoconjugate Targeting CD44v6, in Models of Human Squamous Cell Cancer. 2005;:#A52.
33. M. Baumann, M. Krause, H. Thames, K. Trott, and D. Zips Cancer stem cells and radiotherapy Int J Radiat Biol 85 2009 391 402
34. M. Krause, and M. Baumann Clinical biomarkers of kinase activity: examples from EGFR inhibition trials Cancer Metastasis Rev 27 2008 387 402
35. U. Koch, M. Krause, and M. Baumann Cancer stem cells at the crossroads of current cancer therapy failures-radiation oncology perspective Semin cancer Biol 20 2010 116 124
36. M. Krause, K. Gurtner, Y. Deuse, and M. Baumann Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors Int J Radiat Biol 85 2009 943 954
37. K. Gurtner, Y. Deuse, and R. Bütof Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression Radiother Oncol 99 2011 323 330
38. M. Krause, D. Zips, H.D. Thames, J. Kummermehr, and M. Baumann Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy Radiother Oncol 80 2006 112 122 (Pubitemid 44314014)
39. S.Ø.R.M. Bentzen Quantitative clinical radiobiology Acta Oncol 32 1993 259 275
40. A. Faber, C. Barth, and K. Hormann CD44 as a stem cell marker in head and neck squamous cell carcinoma Oncol Rep 26 2011 321 326
41. S.M. Bentzen, B.M. Atasoy, and F.M. Daley Epidermal growth factor receptor expression in pretreatment biopsies from head, neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial J Clin Oncol 23 2005 5560
42. U.G.A. Sattler, S.S. Meyer, and V. Quennet Glycolytic metabolism and tumour response to fractionated irradiation Radiother Oncol 94 2010 102 109
43. H.P. Rodemann Molecular radiation biology: Perspectives for radiation oncology Radiother Oncol 92 2009 293 298
44. J. Overgaard Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-A systematic review and meta-analysis Radiother Oncol 100 2011 22 32
45. C.A. Maftei, C. Bayer, K. Shi, S.T. Astner, and P. Vaupel Changes in the fraction of total hypoxia and hypoxia subtypes in human squamous cell carcinomas upon fractionated irradiation: Evaluation using pattern recognition in microcirculatory supply units Radiother Oncol 101 2011 209 216
46. A. Lopez-Albaitero, and R.L. Ferris Immune activation by epidermal growth factor receptor-specific monoclonal antibody therapy for head and neck cancer Arch Otolaryngol Head Neck Surg 133 2007 1277 1281 (Pubitemid 350294259)